We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at ...

Most readers would already be aware that Johnson & Johnson's (NYSE:JNJ) stock increased significantly by 11% over ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

The final trades of the day with CNBC’s Dominic Chu and the Fast Money traders. Judge allows DOGE access to Department of ...

Truist Financial Corp reduced its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 11.0% during the fourth quarter, ...

Below is a chart showing DVA's trailing twelve month trading history, with the $190 strike highlighted in orange: Johnson & Johnson (Symbol: JNJ) saw options trading volume of 63,162 contracts ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...